The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

[21] According to treatment guidelines in the Unites States (National Guideline Clearinghouse, https://www.guideline.gov), patients with HBeAg-negative chronic hepatitis B should be considered for ...

Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

Precision BioSciences (DTIL) announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ...

Viral hepatitis is an inflammation of your liver that's caused by a virus. The most common ones in the U.S. are hep A, B, and C. Hepatitis A can make you feel like you have the flu. The first ...

As the number of immunosuppressive drugs has grown, so has the number of patients referred to gastroenterologists with hepatitis B reactivation, which can lead to acute liver failure. For patients ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...

New recommendations address advances in immunosuppressive therapies and highlight antiviral prophylaxis for high-risk patients. Study: AGA Clinical Practice Guideline on the Prevention and ...

Background and Aim: After hepatitis B virus (HBV) e antigen (HBeAg) seroconversion, HBV-DNA continues to replicate, and HBeAg-negative patients still face the risk of liver disease progression.